Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06905054 · ClinicalTrials.gov registry record · Phase 2
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
A Phase 2 study of Primary Sclerosing Cholangitis and Liver Transplant, Complications, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06905054: Recruiting Phase 2 study of Primary Sclerosing Cholangitis and Liver Transplant, Complications, sponsored by Mayo Clinic.
NCT06905054 is a Phase 2 study of Primary Sclerosing Cholangitis and Liver Transplant, Complications that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 80 participants, below the 549-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06905054, a Phase 2 study of Primary Sclerosing Cholangitis and Liver Transplant, Complications, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with
Primary Outcome
Proportion of recipients transplanted for PSC who develop rPSC during a 36-month fenofibrate treatment period, compared to the rate of rPSC in a untreated cohort. The diagnosis of rPSC will be made based on established diagnostic criteria (see Study Design)
Conditions Studied
Interventions
- DRUG Fenofibrate (drug)
- DIAGNOSTIC_TEST Blood draw for the laboratory assessment
- DIAGNOSTIC_TEST MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 2 |
What NCT06905054 shows while recruiting
NCT06905054 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 549-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (85% lower).
The record links to 4 conditions, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 3 interventions - of which Fenofibrate (drug) is the first listed.
NCT06905054 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06905054 about?
NCT06905054 is a clinical study titled "Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation". This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with
What is the current status of trial NCT06905054?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-04-15. Estimated completion is 2028-07-01.
What conditions does trial NCT06905054 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures.
What interventions are being tested in trial NCT06905054?
The interventions under investigation include: Fenofibrate (drug) (DRUG), Blood draw for the laboratory assessment (DIAGNOSTIC_TEST), MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06905054?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06905054 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06905054's enrollment target sits among peer trials
80 12th of 23 higher than 12 of 23 other Primary Sclerosing Cholangitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Sclerosing Cholangitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
RECRUITING · Phase 2
-
Detoxification of the Liver In PSC (Dolphin)
RECRUITING · Phase 2
-
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
ACTIVE NOT RECRUITING · Phase 2
-
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
COMPLETED · Phase 2
-
A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI